When is the next results date for Natco Pharma?

No Upcoming Board Meetings

What does Natco Pharma do?

Natco Pharma Ltd. is a mid-cap pharmaceutical company focused on developing and manufacturing pharmaceutical products, with recent quarterly net sales of ₹1,221 Cr and a net profit of ₹407 Cr. The company has a market cap of ₹15,407 Cr and key metrics include a P/E ratio of 8.00 and a return on equity of 24.79%.

Overview:<BR>Natco Pharma Ltd. is a mid-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on the development and manufacturing of pharmaceutical products.<BR><BR>History:<BR>Natco Pharma Limited was originally incorporated in 1981 as Natco Fine Pharmaceuticals Private Limited. It became a deemed public company in 1992 and changed its name to Natco Pharma Limited in 1993. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,221 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 407 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 15,407 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 8.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.69%<BR>- Debt Equity: -0.29<BR>- Return on Equity: 24.79%<BR>- Price to Book: 2.03<BR><BR>Contact Details:<BR>Address: Natco House, Road No 2 Banjara Hills Hyderabad Telangana : 500033<BR>Tel: 91-040-23547532<BR>Email: investors@natcopharma.co.in<BR>Website: http://www.natcopharma.co.in

Who are in the management team of Natco Pharma?

As of March 2023, the management team of Natco Pharma includes V C Nannapaneni (Managing Director), G S Murthy (Chairman), Rajeev Nannapaneni (CEO), and several other directors and executives responsible for the company's strategic direction and operations.

As of March 2023, the management team of Natco Pharma includes the following key individuals:<BR><BR>1. V C Nannapaneni - Managing Director<BR>2. G S Murthy - Chairman & Independent Director<BR>3. Rajeev Nannapaneni - Director & Chief Executive Officer<BR>4. T V Rao - Non-Executive & Independent Director<BR>5. D G Prasad - Non-Executive & Independent Director<BR>6. Leelaa Digumarti - Non-Executive & Independent Director<BR>7. PSRK Prasad - Vice President & Director<BR>8. MUR Naidu - Non-Executive & Independent Director<BR>9. D Linga Rao - President & Director<BR>10. Pavan Bhat - Vice President & Director<BR>11. Venkat Ramesh - Company Secretary & Compliance Officer<BR><BR>This diverse team is responsible for overseeing the strategic direction and operations of the company.

Who are the peers of the Natco Pharma?

Natco Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Blue Jet Health, Sai Life, Neuland Labs, Sanofi India, and Granules India. In terms of performance, Divi's Lab leads with a 1-year return of 51.69%, while Natco Pharma has a return of -13.51%.

Peers: The peers of Natco Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Blue Jet Health, Sai Life, Neuland Labs., Sanofi India, and Granules India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Blue Jet Health, Neuland Labs., and Granules India, while Good management risk is found at Divi's Lab., Torrent Pharma, and Sai Life. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good growth is noted for Natco Pharma and Sai Life. Below Average growth is seen at Divi's Lab., Torrent Pharma, Blue Jet Health, and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Blue Jet Health, Neuland Labs., and Sanofi India, while Good capital structure is found at Torrent Pharma and Sai Life, and Average at Granules India.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while Natco Pharma has a 1-year return of -13.51%, indicating a significantly lower performance compared to its peers. The peer with the lowest 1-year return is Sanofi India at -28.96%. Additionally, the six-month return is negative for Natco Pharma, Torrent Pharma, Neuland Labs., and Sanofi India.

Who are the top shareholders of the Natco Pharma?

The top shareholders of Natco Pharma include promoter V C Nannapaneni with 15.66%, 54 mutual fund schemes holding 1.85%, and 292 foreign institutional investors (FIIs) with 17.49%. Individual investors own 23.68%, while the highest public shareholder is Belgrave Investment Fund at 2.31%, with no pledged promoter holdings.

The top shareholders of Natco Pharma include the promoters, with V C Nannapaneni being the individual with the highest holding at 15.66%. The company has a diverse shareholder base, with 54 mutual fund schemes collectively holding 1.85% and 292 foreign institutional investors (FIIs) holding 17.49%. Additionally, individual investors own 23.68% of the shares, and the highest public shareholder is Belgrave Investment Fund, which holds 2.31%. Overall, the majority of the shares are held by promoters, and there are no pledged promoter holdings.

How big is Natco Pharma?

As of 24th July, Natco Pharma Ltd. has a market capitalization of 18,196.00 Cr, with recent net sales of 4,429.50 Cr and net profit of 1,885.40 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Natco Pharma Ltd. has a market capitalization of 18,196.00 Cr, categorizing it as a Mid Cap company. <BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 4,429.50 Cr, while the sum of Net Profit for the same period is 1,885.40 Cr. <BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 5,853.10 Cr and Total Assets valued at 6,886.90 Cr.

Are Natco Pharma latest results good or bad?

Natco Pharma's latest results show a 20% increase in net sales to Rs 1,328.90 crore and record cash reserves, indicating positive trends. However, growth rates have slowed compared to the previous quarter, suggesting stable but less robust performance.

Natco Pharma's latest results present a mixed picture. On one hand, the company reported a net sales figure of Rs 1,328.90 crore, which reflects a 20% growth compared to the average of the previous four quarters. This indicates a positive trend in sales performance. Additionally, the company's cash and cash equivalents have reached a record high of Rs 2,176.00 crore, suggesting improved liquidity.<BR><BR>However, when looking at the quarter-on-quarter performance for the quarter ending June 2025, there are signs of slowing growth. The net sales growth of 8.84% and net profit growth of 18.22% are significantly lower than the previous quarter's impressive figures of 157.16% and 205.71%, respectively. This decline in growth rates indicates that while the company is performing well compared to historical averages, it may be facing challenges in maintaining the rapid growth seen earlier.<BR><BR>Overall, while there are positive aspects such as increased sales and liquidity, the slowing growth rates suggest that the results are not as strong as they were in the previous quarter. Therefore, the performance can be seen as stable but not particularly strong in the context of recent trends.

Has Natco Pharma declared dividend?

Yes, Natco Pharma Ltd. has declared a dividend of 100%, amounting to ₹1.5 per share, with an ex-date of August 19, 2025. The dividend yield is 0.66%, and total returns have varied across periods, showing positive performance in the last 3 and 5 years.

Natco Pharma Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 1.5<BR>- Ex-date: 19 Aug 25<BR><BR>Dividend Yield: 0.66%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 5.75%, the dividend return was 0.24%, resulting in a total return of 5.99%.<BR><BR>Over the last 6 months, the price return was -0.96%, the dividend return was 0.40%, leading to a total return of -0.56%.<BR><BR>For the 1-year period, the price return was -39.98%, the dividend return was 0.55%, which resulted in a total return of -39.43%.<BR><BR>In the 2-year period, the price return was 6.25%, the dividend return was 1.19%, giving a total return of 7.44%.<BR><BR>During the 3-year period, the price return was 35.44%, the dividend return was 3.16%, leading to a total return of 38.6%.<BR><BR>For the 4-year period, the price return was -11.74%, the dividend return was 2.60%, resulting in a total return of -9.14%.<BR><BR>In the last 5 years, the price return was 5.53%, the dividend return was 4.13%, culminating in a total return of 9.66%.<BR><BR>Overall, Natco Pharma has declared a significant dividend, and while the total returns show variability across different periods, the recent 3-year and 5-year returns indicate positive performance, particularly in terms of price and dividends.

How has been the historical performance of Natco Pharma?

Natco Pharma has shown significant financial growth from March 2020 to March 2025, with net sales increasing from INR 1,915 crore to INR 4,429.50 crore, and profit after tax rising from INR 458.10 crore to INR 1,883.40 crore, reflecting improved operational efficiency and enhanced shareholder value. Total assets also grew from INR 4,587.80 crore to INR 8,580.70 crore during this period.

Answer:<BR>The historical performance of Natco Pharma shows significant growth in various financial metrics over the years.<BR><BR>Breakdown:<BR>Natco Pharma's net sales have steadily increased from INR 1,915.00 crore in March 2020 to INR 4,429.50 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from INR 1,915.00 crore in March 2020 to INR 4,429.50 crore in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from INR 690.00 crore in March 2020 to INR 2,550.50 crore in March 2025, indicating improved operational efficiency. Profit before tax surged from INR 568.70 crore in March 2020 to INR 2,291.40 crore in March 2025, while profit after tax increased from INR 458.10 crore to INR 1,883.40 crore during the same period. The earnings per share (EPS) rose dramatically from INR 25.32 in March 2020 to INR 105.33 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from INR 4,587.80 crore in March 2020 to INR 8,580.70 crore in March 2025, with total liabilities increasing from INR 4,587.80 crore to INR 8,580.70 crore as well. Cash flow from operating activities improved significantly, reaching INR 1,696.00 crore in March 2025, compared to INR 417.00 crore in March 2020. Overall, Natco Pharma has demonstrated robust financial growth and operational performance over the years.

Is Natco Pharma overvalued or undervalued?

As of November 17, 2025, Natco Pharma is considered an attractive investment opportunity, trading at a PE ratio of 9.55 and showing potential for growth with favorable valuation metrics compared to peers, despite recent underperformance against the Sensex.

As of 17 November 2025, Natco Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.55, an EV to EBIT of 7.93, and a ROCE of 25.97%. These ratios suggest that Natco Pharma is trading at a discount compared to its peers, particularly when compared to Sun Pharma, which has a PE ratio of 36.69, and Divi's Lab, with a PE ratio of 69.78.<BR><BR>In the context of its peer group, Natco Pharma's valuation metrics stand out as more favorable, especially with a PEG ratio of 0.00, indicating potential for growth without the corresponding high valuation. While the stock has underperformed the Sensex over the past year, it has shown resilience with a 3-year return of 43.82%, suggesting that it may be positioned for recovery. Overall, Natco Pharma appears to be a compelling investment opportunity within the pharmaceuticals and biotechnology sector.

Should I buy, sell or hold Natco Pharma?

Is Natco Pharma technically bullish or bearish?

As of December 3, 2025, Natco Pharma's trend is sideways with mixed signals: weekly indicators suggest mild bullishness while monthly indicators are bearish, indicating a lack of strong momentum.

As of 3 December 2025, the technical trend for Natco Pharma has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD and KST indicate a mildly bullish outlook, while the monthly MACD and KST are bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly. Daily moving averages are mildly bearish. Overall, the indicators suggest a lack of strong momentum in either direction, reflecting the sideways trend.

Why is Natco Pharma Ltd. falling/rising?

As of 28-Dec, Natco Pharma Ltd. is facing a decline in its stock price, currently at 908.10, with a year-to-date drop of -34.53%, significantly underperforming compared to the Sensex's gain of +8.83%. Recent trends indicate a continued downward trajectory, despite some positive management metrics.

As of 28-Dec, Natco Pharma Ltd. is experiencing a decline in its stock price, currently at 908.10, which reflects a change of -8.15 (-0.89%). The stock has underperformed relative to the benchmark Sensex, which has shown a slight increase of +0.13% over the past week. Over the past month, Natco Pharma's stock has decreased by -2.03%, while the Sensex has only fallen by -0.66%. <BR><BR>Year-to-date, the stock has significantly underperformed, with a decline of -34.53%, contrasting sharply with the Sensex's gain of +8.83%. This trend continues over a one-year period, where Natco Pharma's stock has dropped by -33.34%, while the Sensex has increased by +8.37%. <BR><BR>The stock has been on a consecutive decline for the last two days, with a total drop of -2.05% during this period. Additionally, there has been a notable decrease in investor participation, as evidenced by a -17.76% drop in delivery volume compared to the five-day average. Although the stock is trading above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, indicating a short-term weakness.<BR><BR>Despite some positive factors such as high management efficiency and a low debt-to-equity ratio, the overall performance and recent trends suggest that the stock is currently in a downward trajectory.

Which are the latest news on Natco Pharma?